Table 1. Demographic characteristics of retrospective cohort.
| All HP (N = 136) | No antigen (N = 21) | 1 antigen (N = 88) | ≥2 antigens (N = 27) | |
|---|---|---|---|---|
| Mean age (SD) | 63.0 (10.9) | 63.2 (7.7) | 61.9 (11.5) | 61 (10.5) |
| Male, No. (%) | 58 (42.6) | 11 (52.4) | 36 (40.9) | 10 (37.0) |
| Ethnicity, No. (%) | ||||
| White | 115 (84.6) | 14 (66.7) | 78 (88.6) | 23 (85.2) |
| Black | 3 (2.2) | 1 (4.8) | 1 (11.4) | 1 (1.1) |
| Hispanic or Latino | 8 (5.9) | 2 (9.5) | 5 (5.7) | 1 (1.1) |
| Asian | 6 (4.4) | 4 (1.9) | 0 (0.0) | 2 (7.4) |
| Other | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Unknown | 4 (2.9) | 0 (0.0) | 4 (4.5) | 0 (0.0) |
| Ever Smoker, No. (%) | 54 (39.7) | 7 (33.3) | 34 (38.6) | 13 (48.1) |
| Pack years, median (IQR) | 15 (6.4–24) | 21 (8–23) | 16.3 (8.1–24.5) | 10 (4–24) |
| Antigen identified, No. (%)* | 115 (84.6) | 0 (0.0) | 88 (100) | 27 (100) |
| Avian | 72 (52.9) | 0 (0.0) | 45 (51.1) | 27 (100) |
| Mold | 58 (42.6) | 0 (0.0) | 34 (38.6) | 24 (88.9) |
| Other** | 13 (9.6) | 0 (0.0) | 9 (10.2) | 4 (14.8) |
| Baseline Lung Function, mean (SD), N | ||||
| FVC % predicted | 67.4 (19.3),134 | 63.3 (20), 20 | 68.7 (19.0),88 | 66.0 (19.0),26 |
| DLCO % predicted | 50.7 (17.4), 134 | 51.0 (22.5), 20 | 50.2 (17.0),88 | 52.2(13.6),26 |
| HRCT Available for Scoring, No. (%) | 136 (100) | 21 (100) | 88 (100) | 27 (100) |
| Lung Biopsy Performed, No. (%)*** | ||||
| Surgical Biopsy | 93 (68.4) | 17 (81.0) | 58 (65.9) | 18 (66.7) |
| Transbronchial | 68 (50) | 6 (28.5) | 45 (51.1) | 17 (63.0) |
| Biopsy | ||||
| Bronchoalveolar Lavage**** | 57 (41.9) | 6 (28.5) | 39 (44.3) | 12 (44.4) |
| Follow Up Time in years, median (IQR) | 3.2 (1.8–5.5) | 1.83 (1.0–3.2) | 3.0 (1.9–5.5) | 2.8 (1.2–4.9) |
| Clinical Outcomes | ||||
| Death, N (%) | 15 (11.0) | 4 (19.0) | 8 (9.1) | 3 (11.1) |
| Transplant, N (%) | 22 (16.2) | 5 (23.8) | 13 (14.8) | 4 (14.8) |
| Transplant-free | 11.1 | 4.89 | 12.8 | 11.2 |
| survival, median | ||||
| years |
*1 patient had 3 antigens identified; the remainder had 2 antigens identified; antigen exposure was identified by history
**Other antigens included isocyanate exposure and fish tank exposure
***30 patients had both SLB and Tbbx
****49 patients had both BAL and TBBx